Healthcare Services

Biologics Outsourcing Market Outlook 2026–2030 with Major Growth Drivers and Emerging Industry Trends

March 30, 2026March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Biologics Outsourcing Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The size of the biologics outsourcing market has experienced rapid expansion in recent years. It is projected to grow from $22.58 billion in 2025 to $25.57 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 13.2%. This historical growth can be attributed to several factors, including rising biologics commercialization activities, increasing capital intensity of biologics facilities, the expansion of biosimilar development programs, the growing complexity of regulatory compliance, and enhanced collaboration between pharmaceutical companies and CDMOs.

The biologics outsourcing market is anticipated to experience substantial expansion over the upcoming years. Its valuation is projected to reach $42.43 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.5%. This projected growth during the forecast period is driven by factors such as a surge in demand for extensive biologics production, increased capital expenditure in manufacturing facilities capable of handling multiple products, the broadening scope of cell and gene therapy outsourcing activities, a heightened emphasis on the robustness of supply chains, and the wider integration of digital manufacturing solutions. Key trends anticipated during this period encompass a rise in the strategic contracting out of biologic manufacturing, an escalating need for comprehensive, end-to-end outsourcing solutions, a growing inclination towards adaptable manufacturing collaborations, the expansion of worldwide CDMO networks, and a heightened commitment to optimizing costs and mitigating risks.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12573&type=smp

What Major Drivers Are Influencing Demand In The Biologics Outsourcing Market?

The increasing incidence of cancer is anticipated to boost the expansion of the biologics outsourcing market in the future. Cancer encompasses a wide range of diseases that can emerge in almost any organ or tissue when abnormal cells multiply without control, extending beyond their normal limits, and either metastasizing to other organs or infiltrating adjacent body areas. The biologics outsourcing sector is crucial in addressing cancer by offering specialized knowledge, facilities, and frameworks for the creation, production, and clinical provision of biologic treatments. These include monoclonal antibodies, immunotherapies, and other targeted biologics employed for the identification, therapy, and management of various cancer types. For example, in January 2023, data from the National Center for Biotechnology Information, a US-based intergovernmental organization, indicated 1,958,310 new cancer cases in the United States, with an estimated 609,820 cancer deaths projected for 2023. Additionally, new cancer cases annually are forecast to climb to 29.5 million, and cancer-related fatalities to 16.4 million by 2040. Consequently, the growing prevalence of cancer cases is propelling the growth of the biologics outsourcing market.

What Major Segment Divisions Exist Within The Biologics Outsourcing Market?

The biologics outsourcing market covered in this report is segmented –

1) By Product Type: Antibodies, Recombinant, Vaccines, Protein, Other Products

2) By Source: Human, Microbial, Other Sources

3) By Application: Oncology, Cellular And Gene Therapy, Blood And Blood-Related Products Development, Vaccine Development, Stem Cell Research, Other Applications

4) By End User: Pharmaceutical Industries, Biotechnology Industries, Contract Development And Manufacturing Organization (CDMO)

Subsegments:

1) By Antibodies: Monoclonal Antibodies, Polyclonal Antibodies

2) By Recombinant: Recombinant Proteins, Recombinant DNA Products

3) By Vaccines: Therapeutic Vaccines, Preventive Vaccines

4) By Protein: Enzymes, Hormones, Cytokines

5) By Other Products: Gene Therapies, Cell Therapies, Biosimilars

How Are Trends Impacting The Biologics Outsourcing Market?

Leading companies in the biologics outsourcing market are concentrating on developing new Contract Development and Manufacturing Organizations (CDMOs) to maintain their market presence. A CDMO is an entity that offers a range of services to pharmaceutical and biotechnology firms, covering the development and production of drugs and other therapeutic products. For example, in October 2023, Tanvex BioPharma USA Inc., a US-based biopharmaceutical developer and manufacturer, launched Tanvex CDMO. This new division of the company delivers comprehensive services for the development and production of biologics, addressing the requirements of the biopharmaceutical industry. Situated in San Diego’s Sorrento Valley biotech hub, Tanvex CDMO features a 100,000-square-foot facility equipped with a cutting-edge Research and Development (R&D) center, two mammalian Good Manufacturing Practice (GMP) manufacturing suites, one microbial GMP manufacturing suite, Quality Control (QC) laboratories, and a GMP warehouse. Building on Tanvex BioPharma USA Inc.’s established expertise, Tanvex CDMO intends to support emerging companies in progressing mammalian and microbial-derived biologics from concept to commercialization, thus significantly bolstering the domain of novel biologics and biosimilars.

Which Companies Are Leading Innovation In The Biologics Outsourcing Market?

Major companies operating in the biologics outsourcing market are AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Lonza Group Ag, Catalent Inc., Sartorius Stedim Biotech S.A., Charles River Laboratories International Inc., WuXi Biologics Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., CordenPharma GmbH, Ajinomoto Bio-Pharma Services, Syngene International Limited, Rentschler Biopharma SE, Albany Molecular Research Inc., KBI Biopharma Inc., Fujifilm Diosynth Biotechnologies Inc., Avid Bioservices Inc., BioVectra Inc., ProBioGen AG, ABL Inc., Vibalogics GmbH, JHL Biotech Inc., Goodwin Biotechnology Inc., Crown Bioscience Inc., Cytovance Biologics Inc., LakePharma Inc., AGC Biologics GmbH, Biomay AG, Polpharma Biologics S.A.

Read the full biologics outsourcing market report here:

https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Biologics Outsourcing Market?

North America was the largest region in the biologics outsourcing market in 2025. The regions covered in the biologics outsourcing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Biologics Outsourcing Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12573&type=smp

Browse Through More Reports Similar to the Global Biologics Outsourcing Market 2026, By The Business Research Company

Biologics Contract Development Global Market Report

https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Advanced Therapeutics Pharmaceutical Outsourcing Global Market Report

https://www.thebusinessresearchcompany.com/report/advanced-therapeutics-pharmaceutical-outsourcing-global-market-report

Medical Device Outsourcing Global Market Report

https://www.thebusinessresearchcompany.com/report/medical-device-outsourcing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795